Physician profile
Kevin C Coss
NPI 1306850532
$3,939.91
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,959 · 2020: $527 · 2021: $16.35 · 2022: $430 · 2023: $804 · 2024: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $550.07 | 2019-2024 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $468.46 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $303.00 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $289.22 | 2019-2024 | Airsupra |
| Allergan, INC. | $228.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $221.79 | 2019 | |
| Alexion Pharmaceuticals, INC. | $193.11 | 2021-2023 | Strensiq |
| Novartis Pharmaceuticals Corporation | $182.60 | 2019-2023 | |
| Glaxosmithkline, LLC. | $177.13 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $154.67 | 2019-2020 | |
| Abbvie INC. | $131.32 | 2020-2023 | Vraylar, Ubrelvy |
| Pfizer INC. | $127.30 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.28 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $97.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $82.21 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $69.26 | 2022 | |
| Eisai INC. | $65.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $47.85 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $43.55 | 2019 | |
| Abbott Laboratories | $42.10 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $41.03 | 2022-2024 | |
| Astellas Pharma US INC | $40.73 | 2019 | |
| Exact Sciences Corporation | $40.70 | 2023 | Cologuard Collection Kit |
| Antares Pharma, INC. | $34.35 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Radius Health, INC. | $27.42 | 2019-2020 | |
| Tempus Ai, INC | $25.62 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $24.26 | 2019 | |
| Corium, LLC | $22.35 | 2024 | Azstarys |
| Ibsa Pharma INC. | $15.70 | 2022 | |
| Mylan Specialty L.P. | $14.45 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Coss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.